Jinhe Biotechnology(SZ:002688)2022-11-21 16:12Group 1: Company Growth Strategy - The company aims to achieve a revenue of approximately 5 billion by 2025, with a net profit of 600 million and a market value of 20 billion [1][5][9] - The strategic plan was developed in 2020 and focuses on the animal health industry, with agricultural product processing and environmental treatment as auxiliary sectors [1][5] Group 2: Stock Performance and Market Communication - The company's stock price has been low for several years, attributed to various factors including market conditions and internal communication issues [2][3] - A share buyback plan has been initiated to boost stock prices, with future measures to be considered based on market conditions [2][3][6] Group 3: Financial Performance and Dividends - The company did not distribute cash dividends in 2021 due to poor performance influenced by upstream and downstream industry factors, and to allocate funds for the share buyback plan [4][9] - The company is focused on maximizing shareholder interests and aims for long-term returns [4][9] Group 4: Product Pricing and Market Conditions - The price of the company's gold mildew product is currently around 19,000 yuan per ton, showing an increase compared to last year [5][8] - The company is preparing to launch a brucellosis vaccine, expected to receive certification in 4-6 months, with production planned for the fourth quarter [8][9] Group 5: Competitive Positioning - The main competitors in the chemical drug sector include companies like Chia Tai Animal Health, with the company holding advantages in production capacity, market scale, and technology [5][9] - The company aims to expand its vaccine business, targeting a revenue of over 700 million by 2025, with a projected budget of 340 million for 2022, reflecting a growth of around 20% [8][9]